Advertisement
Mylan
Subscribe to Mylan

The Lead

Mylan Beats Wall Street Third Quarter Forecasts

October 31, 2014 8:48 am | News | Comments

Mylan has reported earnings of $499.1 million in its third quarter. On a per-share basis, the Canonsburg, Pennsylvania-based company said it had profit of $1.26. Earnings, adjusted for one-time gains and costs, came to $1.16 per share.   

Mylan Recalls Some Lots of Nitroglycerin Spray Used to Treat Angina

October 15, 2014 2:14 pm | by The Canadian Press | News | Comments

Some lots of the product, called Mylan-Nitro Sublingual Spray 0.4 mg Per Metered Dose, are...

Mylan Commences Clinical Trials for Generic Versions of Advair Diskus and Insulin Analog to Lantus

September 16, 2014 8:59 am | News | Comments

Mylan today announced it is initiating Phase III clinical trials for its generic version of...

Mylan to Pay $300M for U.S. Rights to Arixtra Injection

September 10, 2014 7:59 am | News | Comments

Mylan has entered into an agreement to acquire the U.S. commercialization, marketing and...

View Sample

FREE Email Newsletter

Mylan Second Quarter Profit Drops 30%

August 7, 2014 7:35 am | by The Associated Press | News | Comments

Mylan reported profit that declined by 30 percent in its second quarter, and missed analysts' expectations. The Canonsburg, Pennsylvania-based company said net income fell to $125.2 million, or 32 cents per share, from $177.7 million, or 46 cents per share.

Mylan to Buy Abbott's Generic Drugs Business in $5.3B Deal

July 14, 2014 8:17 am | News | Comments

Mylan said Monday that the deal will diversify and expand its business outside the U.S. The combined company will be organized in the Netherlands, which will help reduce its tax expenses, while maintaining its headquarters near Pittsburgh.  

Mylan First Quarter Profit up 8%, Eyeing Acquisitions

May 1, 2014 11:34 am | News | Comments

Mylan's first-quarter net income rose about 8 percent, and the generic drugmaker said Thursday that it is still hunting for acquisitions and it expects to pull off a "substantial transaction" this year.        

Advertisement

Meda Rejects Revised Offer from Mylan

April 28, 2014 7:33 am | by The Associated Press | News | Comments

Swedish pharmaceutical company Meda says it has rejected another offer from U.S. generic drugmaker Mylan Inc. Meda says its board decided to reject a revised Mylan proposal because the deal lacks support from Meda's largest shareholder, which the company did not name in a brief statement.

Mylan Launches Generic ORTHO EVRA Patch

April 17, 2014 8:48 am | News | Comments

Mylan has launched XULANET, the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day).              

Prosonix Licenses Products to Mylan

April 15, 2014 8:45 am | News | Comments

PSX1001 and PSX1050, which are the first products to emerge from Prosonix's innovative and proprietary particle engineering platform, are being developed as generic versions to GlaxoSmithKline's pressurized metered dose inhalers (pMDI) Flixotide® and Flovent®, respectively.

Meda Turns Down Mylan

April 4, 2014 10:57 am | News | Comments

Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses. Meda AB says talks between the two companies have stopped "without further actions."          

Supreme Court Takes Up Drug Company Dispute

March 31, 2014 10:11 am | News | Comments

The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.      

Advertisement

Mylan Wins Breach of Contract Case Against GSK

March 27, 2014 8:50 am | News | Comments

Mylan has announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GSK relating to Paroxetine Hydrochloride Extended-release (ER) Tablets.

Court Upholds Mylan's Patents on Perforomist Inhalation Solution

March 25, 2014 7:26 am | News | Comments

Mylan Inc. has announced the United States District Court for the Northern District of West Virginia issued a decision upholding the validity of all patents asserted by Mylan, protecting Perforomist (formoterol fumarate) Inhalation Solution.

Mylan Fourth Quarter Profit Jumps 11%

February 27, 2014 9:02 am | News | Comments

Shares of Mylan Inc. jumped in premarket trading Thursday as the generic drugmaker reported an 11 percent increase in its fourth-quarter earnings, topping expectations despite a rise in expenses.         

Mylan Recalls 10 Lots of Etomidate Injection

February 14, 2014 1:26 pm | News | Comments

Mylan has announced that its subsidiary Agila Specialties Private Limited is conducting a voluntary nationwide recall to the hospital/user level of 10 lots of Etomidate Injection 2 mg/mL - 10 mL and 20 mL.        

Mylan Named as Gilead's Business Partner for India

January 31, 2014 8:30 am | News | Comments

Mylan Inc. has announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s exclusive branded medicines business partner for India.          

Advertisement

Rakesh Bamzai Joins Mylan as President, India Commercial and Emerging Markets

January 3, 2014 8:32 am | News | Comments

Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry. Prior to joining Mylan, he was president of Marketing at Biocon, where he played a key role in building the company's global biopharmaceutical business.

Mylan-Biocon Receive First Indian Biosimilar Regulatory Approval for Herceptin

November 25, 2013 2:25 pm | News | Comments

Mylan has announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product. The product is a biosimilar to Roche's Herceptin, indicated for the treatment of HER2 overexpressing breast cancer.

Teva Announces Favorable Court Ruling in AZILECT® Patent Infringement Litigation

September 23, 2013 9:16 am | News | Comments

Teva Pharmaceutical today announced the U.S. District Court for the District of New Jersey has issued a favorable ruling in the company’s patent infringement lawsuit against Mylan regarding an AZILECT ® (rasagiline tablets) patent which covers methods of treating Parkinson’s disease (PD).

Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vermont

September 4, 2013 4:05 pm | News | Comments

Mylan Inc. has announced the completion of an 85,000 square foot, three-story expansion project at its transdermal patch facility, operated by Mylan Technologies Inc. (MTI), in St. Albans, Vt.         

Mylan Rises as Company Details its Guidance

August 5, 2013 8:15 am | News | Comments

Shares of Mylan Inc. climbed to an all-time high Friday after the generic drugmaker's outlook over the next five years pleased investors. Mylan expects net income to reach at least $6 per share in 2018, more than double its estimate for 2013, and projects revenue growth of about 13 percent per year through 2018.

Mylan's Second Quarter Profit Jumps 28%

August 1, 2013 12:43 pm | News | Comments

Mylan Inc.'s second-quarter earnings jumped 28 percent, as a drop in expenses helped the generic drugmaker counter sluggish revenue growth. The Canonsburg, Pa., company said Thursday it earned $177.7 million, or 46 cents per share, in the three months that ended June 30. That compares to earnings of $138.6 million, or 33 cents per share, in last year's quarter.

Mylan Launches Portfolio of Women's Care Products in India

June 27, 2013 7:58 am | News | Comments

Mylan Inc., today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a portfolio of Women's Care products in India. The portfolio, which initially will consist of eight products, focuses on therapies such as hormones, pre- and post-natal nutrition and management of premenstrual syndrome (PMS).

Roger Graham Named President of Mylan Specialty

June 24, 2013 8:09 am | News | Comments

Mylan Inc. today announced the appointment of Roger Graham as president of Mylan Specialty. Graham will report to Tony Mauro, president of Mylan North America. Graham joins Mylan from Advandx, a private developer of in-vitro diagnostic tests in the infectious disease space. He was the company's chief commercial officer and developed its growth strategy for the U.S. and European markets.

Valeant Says Generic Approval Could Lower Profit

April 4, 2013 9:58 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. said Thursday that a newly approved generic version of one of its drugs could significantly reduce its profits this year. Mylan Inc. on Wednesday received final approval from the U.S. Food and Drug Administration to sell the first generic version of...

Mylan Announces Fortamet Settlement Agreement

March 14, 2013 8:08 am | News | Comments

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Shionogi Inc. and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This product is the generic version of Shionogi's Fortamet.

Mylan to Buy Agila of India for $1.6B

February 27, 2013 6:08 pm | by The Associated Press | News | Comments

Generic drug maker Mylan Inc. said it will buy Agila Specialties for $1.6 billion in cash, expanding its offerings of injectable drugs and its sales in international markets. Mylan, currently the fourth-largest maker of generic drugs in the world, is buying Agila from Strides Arcolab. It could...

Mylan to Help Market Biocon's Generic Insulin Drugs

February 13, 2013 6:14 pm | by The Associated Press | News | Comments

Mylan Inc. said Wednesday it will help market generic versions of some of the biggest-selling insulin drugs in the world under a new agreement with Biocon Ltd., India's largest biotechnology company by revenue. The companies did not disclose terms of the deal. Mylan said it will have the right...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading